Skip to Main Content

Top of the morning to you, and a fine one it is. Despite the overcast skies, the day is getting off to a good reasonably good start here at the Pharmalot campus, where one short person has left for the local schoolhouse, another is gainfully employed, and the official mascots are happily snoozing. This makes it much easier to focus on the tasks at hand, which include passing along some tidbits that appear below and foraging for interesting items. So time to get cracking. Hope your day goes well and do drop us a line when something interesting pops up …

Merck (MRK) will halve the price of its Keytruda cancer drug for its China launch, following a similar move by Bristol-Myers Squibb (BMY), Caixin reports. Keytruda, a cutting-edge treatment for melanoma, will be priced at $2,613 for a 100-milligram/4-milliliter dose, the lowest price in the world, and about half of what it costs in the U.S. The cheaper pricing comes as the Chinese government pledged to reduce costs and Chinese drug makers are lining up products for approval.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!